Profile data is unavailable for this security.
About the company
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
- Revenue in USD (TTM)0.00
- Net income in USD-19.44m
- Incorporated2014
- Employees16.00
- LocationMonopar Therapeutics Inc1000 Skokie Blvd Ste 350WILMETTE 60091-1146United StatesUSA
- Phone+1 (847) 388-0349
- Fax+1 (302) 655-5049
- Websitehttps://www.monopartx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Forte Biosciences Inc | 0.00 | -51.74m | 373.93m | 16.00 | -- | 4.45 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Climb Bio Inc | 0.00 | -50.75m | 379.11m | 17.00 | -- | 2.14 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 384.19m | 4.00 | -- | 175.07 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 384.30m | 305.00 | -- | 0.6208 | -- | 13.56 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 390.84m | 32.00 | -- | 1.51 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Absci Corp | 2.82m | -114.60m | 390.97m | 156.00 | -- | 1.85 | -- | 138.89 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
| PepGen Inc | 0.00 | -93.56m | 393.93m | 81.00 | -- | 2.41 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 394.40m | 25.00 | -- | -- | -- | 420.92 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
| Benitec Biopharma Inc | 0.00 | -41.82m | 394.49m | 19.00 | -- | 3.27 | -- | -- | -1.18 | -1.18 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -50.76 | -79.73 | -52.87 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
| Monopar Therapeutics Inc | 0.00 | -19.44m | 396.88m | 16.00 | -- | 2.80 | -- | -- | -3.44 | -3.44 | 0.00 | 21.25 | 0.00 | -- | -- | 0.00 | -25.88 | -52.66 | -26.53 | -59.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -85.50 | -- | -- | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 407.81m | 104.00 | 21.03 | 5.76 | 19.23 | 3.27 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
| Tectonic Therapeutic Inc | 0.00 | -67.30m | 411.95m | 51.00 | -- | 1.54 | -- | -- | -3.85 | -3.85 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -30.20 | -- | -32.12 | -- | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -35.40 | -- | -- | -- |
| Lineage Cell Therapeutics Inc | 10.82m | -67.66m | 414.59m | 70.00 | -- | 18.81 | -- | 38.33 | -0.2955 | -0.2955 | 0.0469 | 0.0957 | 0.1162 | -- | 40.66 | 154,514.30 | -72.50 | -20.81 | -81.52 | -24.54 | 97.84 | 90.99 | -624.16 | -331.61 | -- | -- | 0.004 | -- | 6.19 | 22.00 | 13.39 | -- | 5.13 | -- |
| Lenz Therapeutics Inc | 17.50m | -58.88m | 422.73m | 42.00 | -- | -- | -- | 24.16 | -2.11 | -2.11 | 0.6268 | -- | -- | -- | -- | 416,666.70 | -- | -39.77 | -- | -42.56 | -- | -- | -336.47 | -- | -- | -- | -- | -- | -- | -- | 60.07 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Monopar Therapeutics Inc's reporting currency: US Dollar USD
53.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 1.29m | 19.27% |
| Adage Capital Management LPas of 30 Sep 2025 | 659.20k | 9.86% |
| RA Capital Management LPas of 30 Sep 2025 | 511.21k | 7.65% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 261.82k | 3.92% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 213.32k | 3.19% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 182.63k | 2.73% |
| Saturn V Capital Management LPas of 30 Sep 2025 | 155.37k | 2.33% |
| Adar1 Capital Management LLCas of 30 Sep 2025 | 130.00k | 1.95% |
| Geode Capital Management LLCas of 30 Sep 2025 | 84.96k | 1.27% |
| Affinity Asset Advisors LLCas of 30 Sep 2025 | 79.48k | 1.19% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
